Company Filing History:
Years Active: 2010-2024
Title: Alan Collis: Innovator in Cancer Treatment
Introduction
Alan Collis is a prominent inventor based in Lexington, MA (US), known for his significant contributions to the field of cancer treatment. With a total of 11 patents to his name, he has made remarkable strides in developing therapeutic solutions for patients diagnosed with specific genetic mutations.
Latest Patents
Among his latest patents is a groundbreaking method for inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1). This innovation provides a therapeutic approach for patients diagnosed with cancer harboring an IDH-1 mutation. The treatment involves administering a pharmaceutical composition comprising Compound 1, which selectively inhibits 2-HG production from mIDH-1 enzymes, including various R132 mutations such as R132C, R132H, R132L, R132G, and R132S.
Career Highlights
Throughout his career, Alan has worked with notable companies in the pharmaceutical industry, including Forma Therapeutics, Inc. and Aventis Pharmaceuticals Inc. His work has focused on developing innovative treatments that address critical health challenges, particularly in oncology.
Collaborations
Alan has collaborated with esteemed colleagues such as Patrick F. Kelly and Jeff Davis, contributing to the advancement of cancer therapies through shared expertise and innovative research.
Conclusion
Alan Collis stands out as a dedicated inventor whose work in cancer treatment continues to impact the medical field positively. His innovative patents and collaborations reflect his commitment to improving patient outcomes through scientific advancements.
Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.